The FDA has approved a clinical trial for an experimental stem cell therapy that aims to cure HIV patients. Richmond-based Sangamo Biosciences received approval to genetically modify patients’ stem cells and return them to their bodies. The field of research has generated tremendous excitement since Timothy Brown, the so-called “Berlin patient,” became the first person to be cured of HIV — he received a bone marrow transplant from someone with a genetic mutation that causes HIV resistance.
FDA Approves Clinical Trial for Possible HIV Cure
(T.J. Kirkpatrick/Getty Images)
Guests:
John Zaia, chair and professor in the Department of Virology at City of Hope and a principal investigator on the approved FDA clinical trials
Jeff Sheehy, HIV patient advocate on the governing board of the California Institute for Regenerative Medicine (CIRM)
Sponsored